Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/rankl-inhibition-through-osteoprotegerin-blocks-bone-loss-in-sr0mVFSpyL
References (37)
-
JJ Body, P Greipp, RE Coleman (2003)
A phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases, 97
-
A. Mizuno, N. Amizuka, K. Irie, A. Murakami, N. Fujise, Takeshi Kanno, Yasushi Sato, N. Nakagawa, H. Yasuda, S. Mochizuki, T. Gomibuchi, K. Yano, N. Shima, N. Washida, E. Tsuda, T. Morinaga, K. Higashio, H. Ozawa (1998)
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.Biochemical and biophysical research communications, 247 3
-
M. Rocha, J. Malacara, F. Sánchez-Marín, C. Torre, M. Fajardo (2004)
Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial.Journal of periodontology, 75 12
-
J. Lin, I. Chen, D. Duggan (1992)
Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats.Drug metabolism and disposition: the biological fate of chemicals, 20 4
-
L. Hofbauer, S. Khosla, C. Dunstan, D. Lacey, W. Boyle, B. Riggs (2000)
The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone ResorptionJournal of Bone and Mineral Research, 15
-
K. Kirkwood, J. Cirelli, J. Rogers, W. Giannobile (2007)
Novel host response therapeutic approaches to treat periodontal diseases.Periodontology 2000, 43
-
H. Fleisch (1997)
Bisphosphonates: Mechanisms of Action and Clinical Use in Osteoporosis - An UpdateHormone and Metabolic Research, 29
-
P. Bekker, D. Holloway, A. Nakanishi, M. Arrighi, P. Leese, C. Dunstan (2001)
The Effect of a Single Dose of Osteoprotegerin in Postmenopausal WomenJournal of Bone and Mineral Research, 16
-
A. Bamias, E. Kastritis, C. Bamia, L. Moulopoulos, I. Melakopoulos, G. Bozas, V. Koutsoukou, D. Gika, A. Anagnostopoulos, C. Papadimitriou, E. Terpos, M. Dimopoulos (2005)
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 34
-
E. Romas, Natalie Sims, Daphne Hards, M. Lindsay, Julian Quinn, Peter Ryan, Colin Dunstan, T. Martin, M. Gillespie (2002)
Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.The American journal of pathology, 161 4
-
P. Kostenuik (2005)
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.Current opinion in pharmacology, 5 6
-
N. Lane, G. Armitage, P. Loomer, Susan Hsieh, S. Majumdar, H.-Y. Wang, M. Jeffcoat, T. Munoz (2005)
Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.Journal of periodontology, 76 7
-
R. Page, K. Kornman (1997)
The pathogenesis of human periodontitis: an introduction.Periodontology 2000, 14
-
M. Rocha, L. Nava, Carlos Torre, F. Sánchez-Marín, M. Garay-Sevilla, J. Malacara (2001)
Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial.Journal of periodontology, 72 2
-
D. Liu, Jiake Xu, L. Figliomeni, L. Huang, N. Pavlos, Michael Rogers, Albert Tan, Patricia Price, Ming Zheng (2003)
Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction.International journal of molecular medicine, 11 1
-
(2007)
3-D micro-CT image analysis of alveolar bone resorption and repair -
Jian Zhang, Jinlu Dai, Yinghua Qi, D. Lin, Peter Smith, C. Strayhorn, A. Mizokami, Z. Fu, John Westman, E. Keller (2001)
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.The Journal of clinical investigation, 107 10
-
T. Cundy, J. Davidson, M. Rutland, Carolyn Stewart, A. DePaoli (2005)
Recombinant osteoprotegerin for juvenile Paget's disease.The New England journal of medicine, 353 9
-
T. Nakashima, Y. Kobayashi, S. Yamasaki, A. Kawakami, K. Eguchi, H. Sasaki, H. Sakai (2000)
Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.Biochemical and biophysical research communications, 275 3
-
B. Oyajobi, Dirk Anderson, K. Traianedes, Paul Williams, T. Yoneda, G. Mundy (2001)
Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.Cancer research, 61 6
-
Y. Kong, H. Yoshida, I. Sarosi, H. Tan, E. Timms, C. Capparelli, S. Morony, A. Oliveira-dos-Santos, G. Van, A. Itié, W. Khoo, A. Wakeham, C. Dunstan, D. Lacey, T. Mak, W. Boyle, J. Penninger (1999)
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature, 397
-
S. Komatsubara, S. Mori, T. Mashiba, Masako Ito, Jiliang Li, Y. Kaji, T. Akiyama, K. Miyamoto, Yongping Cao, J. Kawanishi, H. Norimatsu (2003)
Long‐Term Treatment of Incadronate Disodium Accumulates Microdamage but Improves the Trabecular Bone Microarchitecture in Dog VertebraJournal of Bone and Mineral Research, 18
-
M. Mogi, J. Otogoto, N. Ota, A. Togari (2004)
Differential Expression of RANKL and Osteoprotegerin in Gingival Crevicular Fluid of Patients with PeriodontitisJournal of Dental Research, 83
-
N. Udagawa, N. Takahashi, H. Yasuda, A. Mizuno, K. Itoh, Y. Ueno, T. Shinki, M. Gillespie, T. Martin, K. Higashio, T. Suda (2000)
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.Endocrinology, 141 9
-
Charles Capparelli, S. Morony, K. Warmington, S. Adamu, D. Lacey, C. Dunstan, B. Stouch, Steven Martin, P. Kostenuik (2003)
Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in RatsJournal of Bone and Mineral Research, 18
-
R. Marx, Y. Sawatari, M. Fortin, V. Broumand (2005)
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 63 11
-
S. Morony, C. Capparelli, I. Sarosi, D. Lacey, C. Dunstan, P. Kostenuik (2001)
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.Cancer research, 61 11
-
C. Capparelli, P. Kostenuik, S. Morony, C. Starnes, B. Weimann, G. Van, S. Scully, M. Qi, D. Lacey, C. Dunstan (2000)
Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.Cancer research, 60 4
-
N. Bucay, I. Sarosi, C. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H. Tan, Wei-wei Xu, D. Lacey, W. Boyle, W. Simonet (1998)
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.Genes & development, 12 9
-
T. Crotti, Malcolm Smith, R. Hirsch, S. Soukoulis, H. Weedon, M. Capone, M. Ahern, D. Haynes* (2003)
Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis.Journal of periodontal research, 38 4
-
Y. Teng, Hai Nguyen, Xuijuan Gao, Y. Kong, R. Gorczynski, Bhagirath Singh, R. Ellen, J. Penninger (2000)
Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection.The Journal of clinical investigation, 106 6
-
W. Simonet, D. Lacey, C. Dunstan, M. Kelley, Ming-Shi Chang, R. Lüthy, Hung Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H. Tan, Geraldine Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, W. Boyle (1997)
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 89
-
D. Mahamed, A. Marleau, M. Alnaeeli, Bhagirath Singh, Xiaoxia Zhang, J. Penninger, Y. Teng (2005)
G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice.Diabetes, 54 5
-
J. Halleen (2003)
Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption.Anticancer research, 23 2A
-
T. Hasegawa, Y. Yoshimura, T. Kikuiri, Y. Yawaka, S. Takeyama, A. Matsumoto, H. Oguchi, T. Shirakawa (2002)
Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells.Journal of periodontal research, 37 6
-
Chan Park, Z. Abramson, M. Taba, Q. Jin, J. Chang, J. Kreider, S. Goldstein, W. Giannobile (2007)
Three-dimensional micro-computed tomographic imaging of alveolar bone in experimental bone loss or repair.Journal of periodontology, 78 2
-
J. Body, P. Greipp, Robert Coleman, T. Facon, F. Geurs, J. Fermand, J. Harousseau, A. Lipton, X. Mariette, Catherine Williams, A. Nakanishi, D. Holloway, Steven Martin, Colin Dunstan, Pirow Bekker (2003)
Skeletal Complications of Malignancy
- Publisher
- Wiley
- Copyright
- © American Academy of Periodontology
- ISSN
- 0022-3492
- eISSN
- 1943-3670
- DOI
- 10.1902/jop.2007.070073
- pmid
- 17608585
- Publisher site
- See Article on Publisher Site
Abstract
Background: Prevention of alveolar bone destruction is a clinical challenge in periodontal disease treatment. The receptor activator of nuclear factor‐kappa B ligand (RANKL) inhibitor osteoprotegerin (OPG) inhibits osteoclastogenesis and suppresses bone resorption.
Journal
Journal of Periodontology – Wiley
Published: Jul 1, 2007
Keywords: ; ; ; ;